Insulet Corporation (NASDAQ:PODD) is one of the. On September 17, Truist Securities analyst Richard Newitter reiterated a “Buy” rating on the company’s stock with the price objective of $365.00.

New Insulet President and CEO Ashley McEvoy. [Image courtesy of Procter & Gamble] While Ashley McEvoy has only been at the helm of Insulet (Nasdaq:PODD) for five months, she’s already seeing the ...

David Bosshard, new Modular Medical head of international operations. [Image from LinkedIn] Modular Medical (Nasdaq:MODD) announced today that it appointed David Bosshard as its new head of ...

Modular Medical (MODD) announced the appointment of David Bosshard as Head of International Operations. With two decades of expertise in scaling ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Insulet Corporation is one of them. Insulet Corporation (NASDAQ:PODD) is a global leader in tubeless insulin ...

ViCentra's Kaleido is "the smallest, thinnest, lightest, most precise insulin patch pump in its class," CEO Tom Arnold said in an interview.

Medical device maker Insulet's new collaboration with Pantone aims to shift sentiment. Here's why it may work.

ACTON, Mass. - Insulet Corporation (NASDAQ:PODD), a $22.7 billion medical device company with impressive 26% year-over-year revenue growth, has partnered with Pantone to create "Omnipod Mango," a new ...